AP-472 for Parkinson's Disease with Motor Fluctuations
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Recruiting
Phase 2
Interventional Study
Parkinson Disease
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 30 – 80
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 150 (estimated)
- Sponsor
- Appello Pharmaceuticals, Inc. · Industry
Who this trial is looking for
This trial is looking for people with Parkinson's disease who have motor fluctuations while taking their medication. Participants will receive either the study drug AP-472 or a placebo for about 12 weeks to see how well it works.
Are You a Good Fit for This Trial?
You may be able to join if
- I am between 30 and 80 years old.
- I have been diagnosed with Parkinson's disease.
- I experience at least 3 hours of OFF time each day.
- I have a MoCA score of 24 or higher.
- I can walk on my own or with a walking aid.
- I can swallow oral medication.
- I have been on a stable Parkinson's medication regimen for at least 4 weeks.
- I take levodopa at least three times daily.
You may not be able to join if
- I have a different type of parkinsonism.
- I have received advanced therapies for Parkinson's in the past.
- I have severe involuntary movements affecting my participation.
- I take medications that block dopamine.
- I use on-demand rescue Parkinson's medications more than three times a week.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.
The study will last about 12 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neithe…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria:
Participants must meet all of the following criteria to take part in the study:
1. Be a man or woman between 30 and 80 years of age at the time of screening.
2. Have a diagnosis of Parkinson's disease, confirmed using standard medical criteria, including slowness of movemen…
Contacts